Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boceprevir with peginterferon alfa-2b and ribavirin in postmenopausal women with chronic hepatitis C genotype 1
2011-002459-33Phase 3Active
- Sponsor
- AOU Policlinico di Modena
- Start
- Sep 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of boceprevir, peginterferon alfa-2b and ribavirin in hepatitis C virus infection (2 cohorts), sponsored by AOU Policlinico di Modena. Primary endpoint: Sustained virologic response improvement. Started Sep 2011; status: active.
02
Drugs
boceprevirpeginterferon alfa-2bribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-002459-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002459-33.